RVNC - Revance Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.257B

Cash

319.7M

Avg Qtr Burn

-52.73M

Short % of Float

19.01%

Insider Ownership

2.44%

Institutional Own.

97.12%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
DAXXIFY (DaxibotulinumtoxinA) Details Pain, Muscle pain	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DAXXIFY (DaxibotulinumtoxinA) (injection) Details Glabellar lines	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DAXXIFY (DaxibotulinumtoxinA) Details Spasticity, Muscle control disorder, Congenital adrenal hyperplasia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DaxibotulinumtoxinA Details Inflammatory disease, Heel Pain	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.